Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 1341

1.

Dietary Intake of Omega-3 fatty acids and Endocrine-related Gynecological Cancer: A Meta-Analysis of Observational Studies.

Hoang T, Myung SK, Pham TT.

Cancer Res Treat. 2018 Oct 17. doi: 10.4143/crt.2018.473. [Epub ahead of print]

2.

Genetic Risk Score, Combined Lifestyle Factors and Risk of Colorectal Cancer.

Cho YA, Lee J, Oh JH, Chang HJ, Sohn DK, Shin A, Kim J.

Cancer Res Treat. 2018 Oct 18. doi: 10.4143/crt.2018.447. [Epub ahead of print]

3.

Laparoscopy Versus Open Nephroureterectomy in Prognostic Outcome of Patients with Advanced Upper Tract Urothelial Cancer: A Retrospective, Multicenter, Propensity-Score Matching Analysis.

Kim SH, Song MK, Kim JK, Hong B, Kang SH, Ku JH, Jeong BC, Seo HK; Urothelial Cancer-Advanced Research and Treatment (UCART) study group.

Cancer Res Treat. 2018 Oct 12. doi: 10.4143/crt.2018.465. [Epub ahead of print]

4.

Dummy Run of Quality Assurance Program before Prospective Study of Hippocampus-Sparing Whole-Brain Radiotherapy (HS-WBRT) and Simultaneous Integrated Boost (SIB) for Multiple Brain Metastases from Non-Small Cell Lung Cancer: Korean Radiation Oncology Group (KROG) 17-06 Study.

Chung E, Noh JM, Lee KC, Kim JH, Chung W, Suh YG, Lee JA, Seol KH, Wu HG, Kim YS, Noh OK, Park JW, Lee DS, Lee J, Kim YS, Park WY, Kang MK, Jo S, Ahn YC.

Cancer Res Treat. 2018 Oct 15. doi: 10.4143/crt.2018.415. [Epub ahead of print]

5.

Axillary Lymph Node Dissection Does Not Improve Post-mastectomy Overall or Disease-Free Survival among Breast Cancer Patients with 1-3 Positive Nodes.

Joo JH, Kim SS, Son BH, Ahn SD, Jung JH, Choi EK, Ahn SH, Lee JW, Kim HJ, Ko BS.

Cancer Res Treat. 2018 Oct 16. doi: 10.4143/crt.2018.438. [Epub ahead of print]

6.

Dynamics of Soluble Programmed Death-Ligand 1 (sPDL1) during Chemotherapy and its Prognostic Implications in Cancer Patients: Biomarker Development in Immuno-Oncology.

Ha H, Bang JH, Nam AR, Park JE, Jin MH, Bang YJ, Oh DY.

Cancer Res Treat. 2018 Oct 5. doi: 10.4143/crt.2018.311. [Epub ahead of print]

7.

Clinical and Genetic Characteristics of BRCA1/2 Mutation in Korean Ovarian Cancer Patients: A Multicenter Study and Literature Review.

Kwon BS, Byun JM, Lee HJ, Jeong DH, Lee TH, Shin KH, Suh DS, Kim KH.

Cancer Res Treat. 2018 Oct 8. doi: 10.4143/crt.2018.312. [Epub ahead of print]

8.

Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib.

Kim S, Kim TM, Kim DW, Kim S, Kim M, Ahn YO, Keam B, Heo DS.

Cancer Res Treat. 2018 Oct 10. doi: 10.4143/crt.2018.052. [Epub ahead of print]

9.

Improved Survival of Cancer Patients Admitted to the Intensive Care Unit between 2002 and 2011 at a U.S. Teaching Hospital.

Sauer CM, Dong J, Celi LA, Ramazzotti D.

Cancer Res Treat. 2018 Oct 10. doi: 10.4143/crt.2018.360. [Epub ahead of print]

11.

Prevalence of PALB2 Germline Mutations in Early-onset and Familial Breast/Ovarian Cancer Patients from Pakistan.

Rashid MU, Khan FA, Muhammad N, Loya A, Hamann U.

Cancer Res Treat. 2018 Oct 11. doi: 10.4143/crt.2018.356. [Epub ahead of print]

12.

Immunohistochemistry Biomarkers Predict Survival in Stage II/III Gastric Cancer Patients: From a Prospective Clinical Trial.

Kim MH, Zhang X, Jung M, Jung I, Park HS, Beom SH, Kim HS, Rha SY, Kim H, Choi YY, Son T, Kim HI, Cheong JH, Hyung WJ, Noh SH, Chung HC.

Cancer Res Treat. 2018 Sep 27. doi: 10.4143/crt.2018.331. [Epub ahead of print]

13.

A Phage Display-Identified Peptide Selectively Binds to Kidney Injury Molecule-1 (KIM-1) and Detects KIM-1-Overexpressing Tumors in vivo.

Haque ME, Khan F, Chi L, Gurung S, Vadevoo SMP, Park RW, Kim DK, Kim SK, Lee B.

Cancer Res Treat. 2018 Oct 1. doi: 10.4143/crt.2018.214. [Epub ahead of print]

14.

Comparison of the 7th and the 8th AJCC Staging System for Non-metastatic D2-Resected Lymph Node‚ÄíPositive Gastric Cancer Treated with Different Adjuvant Protocols.

Yu JI, Lim DH, Lee J, Kang WK, Park SH, Park JO, Park YS, Lim HY, Kim ST, Lee SJ, Kim S, Sohn TS, Lee JH, An JY, Choi MG, Bae JM, Yoo H, Kim K.

Cancer Res Treat. 2018 Oct 1. doi: 10.4143/crt.2018.401. [Epub ahead of print]

15.

Jab1 Silencing Inhibits Proliferation and Sensitizes to Cisplatin in Biliary Tract Cancer.

Nam AR, Kim JW, Park JE, Bang JH, Jin MH, Oh DY, Bang YJ.

Cancer Res Treat. 2018 Oct 1. doi: 10.4143/crt.2018.375. [Epub ahead of print]

16.

Retrospective Study of the Significant Predictive Role of Inflammatory Degree in Initial and Repeat Prostate Biopsy Specimens for Detecting Prostate Cancer.

Kim SH, Park B, Joung JY, Chung J, Seo HK, Lee KH, Park WS.

Cancer Res Treat. 2018 Oct 2. doi: 10.4143/crt.2018.314. [Epub ahead of print]

17.

Dose-Dense Rituximab-CHOP versus Standard Rituximab-CHOP in Newly Diagnosed Chinese Patients with Diffuse Large B-Cell Lymphoma: A Randomized, Multicenter, Open-Label Phase 3 Trial.

Li X, Huang H, Xu B, Guo H, Lin Y, Ye S, Yi J, Li W, Wu X, Wang W, Zhan H, Xie D, Peng J, Cao Y, Pu X, Guo C, Hong H, Wang Z, Fang X, Zhou Y, Lin S, Liu Q, Lin T.

Cancer Res Treat. 2018 Oct 2. doi: 10.4143/crt.2018.230. [Epub ahead of print]

18.

Clinical Benefit of Maintenance Therapy for Advanced Biliary Tract Cancer Patients Showing No Progression after First-Line Gemcitabine Plus Cisplatin.

Hyung J, Kim B, Yoo C, Kim KP, Jeong JH, Chang HM, Ryoo BY.

Cancer Res Treat. 2018 Oct 4. doi: 10.4143/crt.2018.326. [Epub ahead of print]

19.

The Health Burden of Cancer Attributable to Obesity in Korea: A Population-Based Cohort Study.

Lee JE, Nam CM, Lee SG, Park S, Kim TH, Park EC.

Cancer Res Treat. 2018 Oct 4. doi: 10.4143/crt.2018.301. [Epub ahead of print]

20.

A Phase II Study to Evaluate the Safety and Efficacy of Pegteograstim in Korean Breast Cancer Patients Receiving Dose-dense Doxorubicin/cyclophosphamide.

Kim GM, Kim JH, Jeong JH, Cho YU, Kim SI, Park S, Park HS, Kim JY, Sohn J.

Cancer Res Treat. 2018 Sep 19. doi: 10.4143/crt.2018.383. [Epub ahead of print]

Supplemental Content

Loading ...
Support Center